




RealRate

# PHARMACEUTICAL 2022

Biofrontera Inc  
Rank 399 of 471

us.com the alternative.com  
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biofrontera Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 5.0% points. The greatest weakness of Biofrontera Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 135% points below the market average of 275%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 46,421               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 3,450                |
| Liabilities, Current                        | 13,836               |
| Liabilities, Non-Current                    | 5,649                |
| Other Assets                                | 3,081                |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 12,845               |
| Other Liabilities                           | 22,396               |
| Other Net Income                            | -12,456              |
| Other Revenues                              | 24,100               |
| Property and Equipment                      | 267                  |
| Research and Development                    | 0                    |
| Selling, General and Administrative Expense | 36,512               |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 53,219               |
| Liabilities                 | 41,881               |
| Expenses                    | 49,357               |
| Revenues                    | 24,100               |
| Stockholders Equity         | 11,338               |
| Net Income                  | -37,713              |
| Comprehensive Net Income    | -37,713              |
| BaseVar                     | 90,506               |
| ECR before LimitedLiability | -27%                 |
| Economic Capital Ratio      | 140%                 |